Mercator MedSystems
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Mercator MedSystems sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,751 sponsors by registered trial count).
Mercator MedSystems: 7 sponsored US clinical trials, 3 recruiting.
Mercator MedSystems sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Iliofemoral; Thrombosis, with 2 trials.
Upper-quartile sponsor footprint
Mercator MedSystems sits in the upper quartile of the sponsor corpus (#1,806 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
NCT04433572
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
NCT04862468
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
NCT03942601
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
NCT02469532
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
NCT02066103
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
NCT01983449
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Mercator MedSystems pipeline
3 recruiting of 7 indexed (43% open); 3 completed (43%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Iliofemoral; Thrombosis (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.